top of page

NCI-2021-09617

A Multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer


The study is testing a combination of two medicines for a specific type of breast cancer that has a protein called Androgen Receptor, which is usually found in male hormones. The cancer cells in this type of cancer respond to this protein. However, they don't have another protein called HER2. The study is focused on two medicines: Abemaciclib: This is a medicine that can slow down the growth of cancer cells by targeting specific proteins. Bicalutamide: This medicine is used to block the effects of male hormones. The study wants to see if using Abemaciclib together with Bicalutamide can work well in treating this specific type of breast cancer. They're checking if this combination can help shrink the cancer and slow its growth. In Phase IB, they'll start with a smaller dose and see how people react to it. If it's safe and well-tolerated, they'll move on to Phase II, where they'll give this combination to a larger group to get more information about how well it works.


For more information about the trial, click the link below:

NCI-2021-09617

Clinical Trial Site: Mount Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

bottom of page